

# Marker Therapeutics Inc

12:23 04 Jan 2019

## Cancer-focused Marker Therapeutics shares rise after update on clinical trial pipeline

Marker Therapeutics Inc (NASDAQ:MRKR) saw its shares advance over 9% on the Nasdaq Friday after it updated investors on its clinical pipeline.

The Houston, Texas-based immuno-oncology group gave an update on five clinical trials using its targeted T-cell (MultiTAA) therapies and TPIV200, the group's peptide cancer vaccine product candidate.

In the latter (TPIV200) the group said enrolment of patients had been completed in a Phase 2 trial evaluating the drug as a therapy in patients of ovarian cancer in their first remission after surgery and platinum-based chemotherapy.

Interim data should be available by the year-end, the firm told investors.

In the triple-negative breast cancer trial, initial data from a dose-finding study of TPIV200 as maintenance therapy following first-line treatment showed a 96% immune response rate.

Elsewhere, in the lymphoma trial, 15 heavily pre-treated patients have been treated in a phase 1/2 study, the company said.

No relapses and no cases of cytokine release syndrome have been observed, while four of the six complete responders have remained in remission for three to 42 months post-infusion.

In acute lymphoblastic leukaemia, preliminary Phase 1 data showed a complete response rate of 88% over one to 22 months, the company revealed.


In the multiple myeloma trial, interim data from a Phase 1/2 trial showed an initial 100% disease control rate, including one complete responder and two partial responders, but three patients progressed after three to seven months.

Shares in New York added 9% to \$6.40.

**Price:** 3.2

**Market Cap:** \$146.32 m

### 1 Year Share Price Graph



January 2019 July 2019 January 2020

### Share Information

**Code:** MRKR

**Listing:** NASDAQ

<b>52 week</b>	<b>High</b>	<b>Low</b>
	9.16	2.63

**Sector:** Pharma & Biotech

**Website:**

### Company Synopsis:

*Marker Therapeutics Inc is a clinical-stage immuno-oncology company with the potential to significantly disrupt the current cell therapy landscape. The company is developing a portfolio of non-genetically modified, multi-antigen T cell therapies, which are able to recognize and kill heterogeneous tumors more effectively than conventional single-antigen CAR-T/TCR approaches.*

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a

security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.